ALK and non-small cell lung carcinoma: All these ALK-TKI compounds are encountered as possible front-line treatment options in ALK-rearranged NSCLC in the international guidelines [17,18] with higher evaluation (IA; MCBS 4; ESCAT I-A) for alectinib, brigatinib and lorlatinib.